Information Provided By:
Fly News Breaks for October 21, 2016
ALKS
Oct 21, 2016 | 05:49 EDT
Credit Suisse analyst Vamil Divan raised his price target for Alkermes to $70 after the company announced positive data for the third Phase III study of anti-depression drug ALKS 5461. The analyst added the drug back into his model with a 60% probability of success. Divan assumes a peak sales potential of $1.2B "given the unmet need in treatment-resistant depression." The analyst maintains an Outperform rating on Alkermes.
News For ALKS From the Last 2 Days
There are no results for your query ALKS